Symtuza pill image

Symtuza

DRV/COBI/FTC/TAF darunavir/cobicistat/emtricitabine/tenofovir alafenamide

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily with food for treatment-naïve individuals or individuals with suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to the darunavir or tenofovir components of the regimen. Tablet contains 800 mg darunavir, boosted by 150 mg cobicistat, with 200 mg emtricitabine and 10 mg TAF.

For adults and children weighing at least 88 pounds (40 kg). Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose. Dose cannot be adjusted for people with kidney or liver problems. Symtuza can be used by people with an estimated creatinine clearance of at least 30 mL/ min. It should not be used by people who have severe kidney or liver impairment. Symtuza is not recommended during pregnancy due to substantially lower exposures of darunavir and cobicistat components during pregnancy.
  • See the individual drugs contained in Symtuza: Prezista, Tybost, and Descovy.
  • See package insert for more complete information on potential side effects and interactions.

Manufacturer

Janssen Therapeutics
800) JANSSEN (526-7736)
janssen.com; symtuza.com

AWP

$4,877.76/month

Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments